News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
Market Access Policy in Focus: What’s new with CMS drug price negotiation,... Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.
News SCOTUS won't hear pharma's IRA complaints The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.
News Poll finds Americans cutting back elsewhere to fund health Many Americans are forced to make difficult trade-offs with living expenses and delay life events like retirement to afford health, says a new poll.
News AZ takes Medicare negotiation appeal to SCOTUS AstraZeneca has elevated its challenge to Medicare drug price negotiation powers to the Supreme Court of the US.
Market Access Pharma go-to-market transformation: Why cross-functional sil... Pharmaceutical go-to-market transformation has become the industry's most urgent priority, yet cross-functional coordination remains pharma's biggest challenge.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.